Department of Psychology, University of Toronto, Toronto, ON, Canada.
Department of Psychology, York University, Toronto, ON, Canada.
Psychopharmacology (Berl). 2019 Feb;236(2):731-740. doi: 10.1007/s00213-018-5106-2. Epub 2019 Jan 2.
Microdosing psychedelics-the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin-is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties, microdosing mayprovide complementary clinical benefits using lower-risk, non-hallucinogenic doses.
This pre-registered study aimed to investigate whether microdosing psychedelics is related to differences in personality, mental health, and creativity.
In this observational study, respondents recruited from online forums self-reported their microdosing behaviors and completed questionnaires concerning dysfunctional attitudes, wisdom, negative emotionality, open-mindedness, and mood. Respondents also performed the Unusual Uses Task to assess their creativity.
Current and former microdosers scored lower on measures of dysfunctional attitudes (p < 0.001, r = - 0.92) and negative emotionality (p = 0.009, r = - 0.85) and higher on wisdom (p < 0.001, r = 0.88), openmindedness(p = 0.027, r = 0.67), and creativity (p < 0.001, r = 0.15) when compared to non-microdosing controls.
These findings provide promising initial evidence that warrants controlled experimental research to directly test safety and clinical efficacy. As microdoses are easier to administer than full-doses, this new paradigm has the exciting potential to shape future psychedelic research.
微剂量摄入迷幻剂——有规律地摄入少量迷幻物质，如 LSD 或裸盖菇素——是流行文化中的一种新兴趋势。最近关于全剂量迷幻心理疗法的研究显示，其对心理健康有很大益处，尤其是对抑郁和临终焦虑。虽然全剂量疗法具有改变感知的特性，但微剂量可能会通过使用低风险、非致幻剂量提供补充的临床益处。
这项预先注册的研究旨在调查微剂量摄入迷幻剂是否与个性、心理健康和创造力的差异有关。
在这项观察性研究中，从在线论坛招募的受访者自我报告了他们的微剂量行为，并完成了关于功能失调态度、智慧、负性情绪、开放性和情绪的问卷。受访者还完成了不寻常用途任务，以评估他们的创造力。
当前和以前的微剂量使用者在功能失调态度量表上的得分较低（p<0.001，r=-0.92），负性情绪得分较低（p=0.009，r=-0.85），智慧得分较高（p<0.001，r=0.88），开放性得分较高（p=0.027，r=0.67），创造力得分较高（p<0.001，r=0.15），与非微剂量对照组相比。
这些发现提供了有希望的初步证据，需要进行对照实验研究以直接测试安全性和临床疗效。由于微剂量比全剂量更容易管理，因此这种新方法具有塑造未来迷幻研究的令人兴奋的潜力。
